| Pharmacodynamic measures within tumors expose differential activity of PD (L)-1 antibody therapeutics D Kumar, A Mishra, A Lisok, R Kureshi, S Shelake, D Plyku, R Sen, ... Proceedings of the National Academy of Sciences 118 (37), e2107982118, 2021 | 35 | 2021 |
| Gallium-68–labeled peptide PET quantifies Tumor exposure of PD-L1 therapeutics A Mishra, D Kumar, K Gupta, G Lofland, AK Sharma, DS Banka, ... Clinical Cancer Research 29 (3), 581-591, 2023 | 20 | 2023 |
| Hard superellipse phases: particle shape anisotropy & curvature I Torres-Díaz, RS Hendley, A Mishra, AJ Yeh, MA Bevan Soft Matter 18 (6), 1319-1330, 2022 | 14 | 2022 |
| Non-invasive PD-L1 quantification using [18F] DK222-PET imaging in cancer immunotherapy A Mishra, K Gupta, D Kumar, G Lofland, AK Sharma, LB Solnes, SP Rowe, ... Journal for immunotherapy of cancer 11 (10), e007535, 2023 | 12 | 2023 |
| CD38‐Specific Gallium‐68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET AK Sharma, K Gupta, A Mishra, G Lofland, I Marsh, D Kumar, G Ghiaur, ... Advanced Science 11 (16), 2308617, 2024 | 8 | 2024 |
| PET/MRI and bioluminescent imaging identify hypoxia as a cause of programmed cell death ligand 1 image heterogeneity KM Parkins, B Krishnamachary, D Jacob, SM Kakkad, M Solaiyappan, ... Radiology: Imaging Cancer 5 (4), e220138, 2023 | 4 | 2023 |
| Multiparatopic antibodies induce targeted downregulation of programmed death-ligand 1 SD Ludwig, B Meksiriporn, J Tan, R Kureshi, A Mishra, KJ Kaeo, A Zhu, ... Cell chemical biology 31 (5), 904-919. e11, 2024 | 1 | 2024 |
| A nectin-4 PET radiotracer for pharmacodynamic evaluation of enfortumab vedotin (EV) therapy in urothelial carcinoma A Mishra, AK Sharma, K Gupta, BA Johnson, DJ McConkey, ... Cancer Research 84 (6_Supplement), 2579-2579, 2024 | 1 | 2024 |
| A Gallium-68-Labeled Peptide Radiotracer For CD38-Targeted Imaging In Multiple Myeloma With PET AK Sharma, K Gupta, A Mishra, G Lofland, I Marsh, D Kumar, G Ghiaur, ... bioRxiv, 2023.05. 09.540036, 2023 | | 2023 |
| Non-invasive detection of pancreatic adenocarcinoma using Ga-68 labelled epha2 targeting peptide AK Sharma, K Gupta, A Mishra, S Chen, G Lofland, T Armstrong, ... Cancer Research 83 (7_Supplement), 2768-2768, 2023 | | 2023 |
| PD-L1 PET quantifies the pharmacodynamic effects of immunotherapy A Mishra, D Kumar, K Gupta, PM Forde, E Gabrielson, S Nimmagadda Cancer Research 82 (12_Supplement), 2477-2477, 2022 | | 2022 |
| Imaging pancreatic ductal adenocarcinoma using an EphA2 receptor tyrosine kinase binding 68Ga-labeled peptide radiotracer K Gupta, AK Sharma, A Mishra, SY Chen, G Lofland, TM Armstrong, ... Cancer Research 82 (12_Supplement), 2481-2481, 2022 | | 2022 |
| A highly specific 18F-labelled peptide for non-invasive quantification of PD-L1 levels in tumors D Kumar, A Mishra, A Lisok, S Shelake, B Wharram, R Desilva, R Mease, ... Cancer Research 80 (16_Supplement), 3448-3448, 2020 | | 2020 |
| Non-invasive quantification of pharmacodynamic effects of an antibody targeting PSMA by PET imaging A Mishra, Z Nováková, A Lisok, D Kumar, RC Mease, C Bařinka, ... Cancer Research 80 (16_Supplement), 2779-2779, 2020 | | 2020 |
Sridhar NimmagaddaProfessor of Radiology and Oncology, Johns Hopkins UniversityGeverifieerd e-mailadres voor jhmi.edu